Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor

被引：116
作者：
Aktas, Y
Andrieux, K [1 ]
Alonso, MJ
Calvo, P
Gürsoy, RN
Couvreur, P
Çapan, Y
机构：
[1] Univ Paris Sud, Fac Pharm, CNRS, UMR 8612, F-92296 Chatenay Malabry, France
[2] Hacettepe Univ, Fac Pharm, Dept Pharmaceut Technol, TR-06100 Ankara, Turkey
[3] Univ Santiago de Compostela, Dept Pharmaceut Technol, Sch Pharm, Santiago De Compostela 15782, Spain
来源：
INTERNATIONAL JOURNAL OF PHARMACEUTICS | 2005年 / 298卷 / 02期
关键词：
chitosan; nanoparticles; Z-DEVD-FMK; HPLC;
D O I：
10.1016/j.ijpharm.2005.03.027
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The aim of this work was to develop a formulation for Z-DEVD-FMK, a peptide which is a caspase inhibitor and has been used in experimental animal studies for a decade. Peptide loaded chitosan nanoparticles were obtained by ionotropic gelation process and Z-DEVD-FMK was quantified by an HPLC method. The influence of the initial peptide concentration on the nanoparticle characteristics and release behavior was evaluated. The CS nanoparticles have a particle diameter (Z-average) ranging from approximately 313-412 nm and a positive zeta potential (20-28 mV). The formulation with the initial peptide concentration of 400 ng/ml provided the highest loading capacity (0.46%) and the highest extent of release (65% at 24 h) suggesting the possibility to achieve a therapeutic dose. According to the data obtained, this chitosan-based nanotechnology opens new and interesting perspectives for anticaspase activity. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码：378 / 383
页数：6
相关论文
共 19 条
[1]   The potential of chitosan in ocular drug delivery [J].
Alonso, MJ ;
Sánchez, A .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2003, 55 (11) :1451-1463
[2]   Chitosan as a nasal delivery system: The effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers [J].
Aspden, TJ ;
Mason, JDT ;
Jones, NS ;
Lowe, J ;
Skaugrud, O ;
Illum, L .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (04) :509-513
[3]   The blood-brain barrier: an overview - Structure, regulation, and clinical implications [J].
Ballabh, P ;
Braun, A ;
Nedergaard, M .
NEUROBIOLOGY OF DISEASE, 2004, 16 (01) :1-13
[4]   Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting [J].
Brigger, I ;
Morizet, J ;
Aubert, G ;
Chacun, H ;
Terrier-Lacombe, MJ ;
Couvreur, P ;
Vassal, G .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (03) :928-936
[5]   Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery [J].
Calvo, P ;
Gouritin, B ;
Chacun, H ;
Desmaële, D ;
D'Angelo, J ;
Noel, JP ;
Georgin, D ;
Fattal, E ;
Andreux, JP ;
Couvreur, P .
PHARMACEUTICAL RESEARCH, 2001, 18 (08) :1157-1166
[6]  
Calvo P, 1997, J APPL POLYM SCI, V63, P125, DOI 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO
[7]  
2-4
[8]   Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat [J].
Calvo, P ;
Gouritin, B ;
Villarroya, H ;
Eclancher, F ;
Giannavola, C ;
Klein, C ;
Andreux, JP ;
Couvreur, P .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2002, 15 (08) :1317-1326
[9]  
Chen J, 1998, J NEUROSCI, V18, P4914
[10]   Chitosan nanoparticles:: a new vehicle for the improvement of the delivery of drugs to the ocular surface.: Application to cyclosporin A [J].
De Campos, AM ;
Sánchez, A ;
Alonso, MJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 224 (1-2) :159-168
12